Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature-Reference-Cited by-同舟云学术

Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature

Published:2017-10-09 Issue:4 Volume:23 Page:212-220
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Ongoren Seniz¹,Eskazan Ahmet Emre¹^ORCID,Suzan Veysel²,Savci Sercan²,Erdogan Ozunal Isil¹,Berk Selin¹,Yalniz Fevzi Fırat¹,Elverdi Tugrul¹,Salihoglu Ayse¹,Erbilgin Yucel³,Iseri Sibel Aylin³,Ar Muhlis Cem¹,Baslar Zafer¹,Aydin Yildiz¹,Tuzuner Nukhet⁴,Ozbek Ugur³,Soysal Teoman¹

Affiliation:

1. Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey

2. Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey

3. Department of Genetics, Institute of Experimental Medicine (DETAE), Istanbul University, Istanbul, Turkey

4. Department of Pathology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10245332.2017.1385193

Reference24 articles.

1. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

2. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

3. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

4. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

5. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies;Medical Oncology;2023-05-10

2. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results;Leukemia;2023-03-22

3. Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience;Frontiers in Oncology;2023-03-16

4. Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review;Therapeutic Advances in Hematology;2023-01

5. Small Molecules as Promising Tool for Targeted Cancer Therapies: An Overview of the Twenty-First Century;Drugs and a Methodological Compendium;2023